Head to Head Review: Predictive Technology Group (OTCMKTS:PRED) vs. Matinas Biopharma (NYSE:MTNB)

Predictive Technology Group (OTCMKTS:PRED) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Profitability

This table compares Predictive Technology Group and Matinas Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Predictive Technology Group	N/A	N/A	N/A
Matinas Biopharma	N/A	-123.06%	-94.28%

Volatility and Risk

Predictive Technology Group has a beta of -0.77, meaning that its share price is 177% less volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Institutional & Insider Ownership

11.8% of Matinas Biopharma shares are held by institutional investors. 9.6% of Matinas Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Predictive Technology Group and Matinas Biopharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Technology Group	N/A	N/A	N/A	N/A	N/A
Matinas Biopharma	$1.10 million	2.82	-$22.94 million	($4.85)	-0.13

Predictive Technology Group has higher earnings, but lower revenue than Matinas Biopharma.

Analyst Ratings

This is a breakdown of recent recommendations for Predictive Technology Group and Matinas Biopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Technology Group	0	0	0	0	0.00
Matinas Biopharma	0	2	0	0	2.00

Given Predictive Technology Group’s higher probable upside, equities research analysts clearly believe Predictive Technology Group is more favorable than Matinas Biopharma.

Summary

Matinas Biopharma beats Predictive Technology Group on 5 of the 8 factors compared between the two stocks.

About Predictive Technology Group

Predictive Technology Group, Inc., together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic, therapeutic, and human cellular and tissue-based products (HCT/Ps). It operates in two segments, Human Cellular and Tissues Products (HCT/Ps); and Diagnostics and Therapeutics. The company provides FertilityDX, a genetic testing service for couples experiencing infertility; ARTguide, a genetic test for women experiencing infertility because of endometriosis and other genetic conditions; and regenerative medicine products, including AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte for use in regenerative medicine applications. It has a collaboration agreement with Atrin Pharmaceuticals LLC to develop molecular diagnostic tools to facilitate enhanced selection of cancer patients. The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah. On November 9, 2023, Predictive Technology Group, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Utah. On January 12, 2024, the voluntary petition of Predictive Technology Group, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on November 9, 2023.

About Matinas Biopharma

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead’s antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.